DropsMRP Under Process
Official PMBI MRP is being updated for catalog code 2486.
Locate Jan Aushadhi KendraClinical Overview
Travoprost (0.004% w/v, alone or with Timolol 0.5%) is a synthetic prostaglandin F2-alpha analogue and full selective FP prostanoid receptor agonist on the WHO Model List of Essential Medicines. It significantly enhances uveoscleral aqueous outflow. Indicated for lowering intraocular pressure in open-angle glaucoma and ocular hypertension.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Instill one drop into affected eye(s) once daily in the evening. Apply nasolacrimal occlusion for 1-2 minutes.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Ocular hyperemia, decreased visual acuity, foreign body sensation, eyelash darkening/lengthening, iris color changes. Rare/Severe: Macular edema and intraocular inflammation.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Permanent iris darkening can occur. Remove contact lenses before instilling. Avoid touching the dropper tip to any surface.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or ophthalmic treatment recommendations. Always consult a registered ophthalmologist or ENT specialist before initiating, changing, or instilling any ophthalmic or otic medication.
Timolol Maleate Eye Drops 0.5 %
Timolol Maleate (0.5% w/v) is a non-selective beta-1 and beta-2 adrenergic receptor antagonist on the WHO Model List of Essential Medicines. It blocks beta-adrenergic receptors on non-pigmented ciliary epithelial cells, inhibiting cyclic AMP synthesis and reducing aqueous humor secretion by 30-50% without altering pupillary size or accommodation. Indicated for lowering elevated intraocular pressure in patients with chronic open-angle glaucoma and ocular hypertension.
Brimonidine Tartrate 0.2%w/v + Timolol Maleate 0.5%w/v Ophthalmic Solution
Timolol Maleate (0.5% w/v) is a non-selective beta-1 and beta-2 adrenergic receptor antagonist on the WHO Model List of Essential Medicines. It blocks beta-adrenergic receptors on non-pigmented ciliary epithelial cells, inhibiting cyclic AMP synthesis and reducing aqueous humor secretion by 30-50% without altering pupillary size or accommodation. Indicated for lowering elevated intraocular pressure in patients with chronic open-angle glaucoma and ocular hypertension.
Dorzolamide 2% w/v + Timolol 0.5% w/v Eye Drops
Timolol Maleate (0.5% w/v) is a non-selective beta-1 and beta-2 adrenergic receptor antagonist on the WHO Model List of Essential Medicines. It blocks beta-adrenergic receptors on non-pigmented ciliary epithelial cells, inhibiting cyclic AMP synthesis and reducing aqueous humor secretion by 30-50% without altering pupillary size or accommodation. Indicated for lowering elevated intraocular pressure in patients with chronic open-angle glaucoma and ocular hypertension.
Travoprost Ophthalmic Solution 0.004%w/v
Travoprost (0.004% w/v, alone or with Timolol 0.5%) is a synthetic prostaglandin F2-alpha analogue and full selective FP prostanoid receptor agonist on the WHO Model List of Essential Medicines. It significantly enhances uveoscleral aqueous outflow. Indicated for lowering intraocular pressure in open-angle glaucoma and ocular hypertension.